


CPL207280

Cat. No.:	HY-160602
CAS No.:	2361497-72-3
Molecular Formula:	C ₁₈ H ₂₂ O ₃
Molecular Weight:	286.37
Target:	Free Fatty Acid Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β -cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes ^{[1][2]} .
In Vivo	PL207280 (10 mg/kg; p.o.; single dose) exhibits hypoglycemic effects in Wistar Han rats, with (3 mg/kg; p.o.; single dose) pharmacokinetic parameters of C _{max} , T _{max} , and T _{1/2} being 1699 ng/mL, 1 h, and 1.41 h, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Mach M, et al. Discovery and development of CPL207280 as new GPR40/FFA1 agonist. Eur J Med Chem. 2021;226:113810.
- [2]. Bazydlo-Guzenda K, et al. CPL207280-a novel GPR40/FFA1-specific agonist shows a favorable safety profile and exerts anti-diabetic effects in type 2 diabetic animals[J]. Molecular Pharmacology, 2021.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA